This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
time pcr | 3081 |
nucleic acid | 2804 |
respiratory tract | 2349 |
chain reaction | 2319 |
pcr assay | 2265 |
polymerase chain | 2245 |
stem cell | 2218 |
acute respiratory | 2083 |
reverse transcription | 1673 |
time rt | 1666 |
respiratory viruses | 1624 |
mg kg | 1610 |
influenza virus | 1555 |
respiratory syndrome | 1500 |
pcr assays | 1404 |
gene expression | 1401 |
bone marrow | 1368 |
cell transplantation | 1315 |
cell lines | 1283 |
novel coronavirus | 1260 |
present study | 1258 |
viral rna | 1237 |
severe acute | 1195 |
blood donors | 1193 |
performed using | 1165 |
viral load | 1165 |
significantly higher | 1131 |
clinical samples | 1111 |
peripheral blood | 1099 |
clinical signs | 1095 |
control group | 1088 |
respiratory syncytial | 1061 |
whole blood | 1038 |
infectious diseases | 1017 |
syncytial virus | 999 |
median age | 994 |
cell culture | 987 |
cord uid | 974 |
doc id | 974 |
risk factors | 967 |
coronavirus disease | 966 |
flow cytometry | 953 |
virus infection | 934 |
public health | 931 |
influenza viruses | 922 |
amino acid | 900 |
significant difference | 897 |
isothermal amplification | 895 |
epithelial cells | 890 |
ng ml | 886 |
chest ct | 884 |
pcr products | 880 |
statistically significant | 875 |
immune response | 870 |
cell line | 870 |
viral infections | 865 |
nucleic acids | 862 |
blood samples | 847 |
blood transfusion | 845 |
united states | 840 |
multiplex pcr | 827 |
reverse transcriptase | 821 |
stem cells | 818 |
real time | 816 |
lower respiratory | 808 |
clinical specimens | 771 |
mean age | 760 |
positive samples | 756 |
study design | 748 |
rapid detection | 745 |
tract infections | 743 |
red blood | 739 |
significant differences | 736 |
years old | 730 |
pcr testing | 727 |
hematopoietic stem | 715 |
human metapneumovirus | 714 |
nested pcr | 709 |
one patient | 702 |
patients received | 680 |
mediated isothermal | 661 |
positive results | 656 |
respiratory virus | 652 |
mass spectrometry | 647 |
pcr amplification | 644 |
results suggest | 643 |
two groups | 633 |
cd cells | 629 |
overall survival | 628 |
important role | 626 |
extracellular vesicles | 624 |
breast cancer | 621 |
syndrome coronavirus | 617 |
blood cells | 610 |
western blot | 605 |
respiratory infections | 603 |
nervous system | 595 |
respiratory disease | 590 |
pcr results | 590 |
test results | 589 |
pcr test | 588 |
electron microscopy | 587 |
mg dl | 573 |
copies ml | 571 |
present document | 571 |
summary conclusion | 570 |
en el | 569 |
cystic fibrosis | 565 |
previously described | 561 |
blood components | 560 |
high risk | 555 |
avian influenza | 554 |
upper respiratory | 548 |
viral infection | 544 |
intensive care | 544 |
blood donation | 541 |
serum samples | 540 |
commercially available | 540 |
escherichia coli | 531 |
cd cd | 531 |
gel electrophoresis | 523 |
blood products | 522 |
infectious disease | 520 |
previous studies | 517 |
dna polymerase | 513 |
tract infection | 512 |
protein expression | 512 |
conditioning regimen | 509 |
body weight | 509 |
least one | 508 |
immune system | 506 |
sybr green | 504 |
pcr tests | 504 |
tested positive | 504 |
acquired pneumonia | 502 |
red cell | 502 |
applied biosystems | 501 |
case studies | 500 |
significantly lower | 499 |
blood pressure | 497 |
quantitative pcr | 496 |
lymph node | 494 |
blood group | 492 |
summary conclusions | 491 |
simultaneous detection | 491 |
mg ml | 489 |
blood cell | 488 |
negative results | 488 |
copy number | 483 |
time reverse | 481 |
two patients | 481 |
background case | 481 |
lymph nodes | 477 |
mrna expression | 473 |
may also | 472 |
university hospital | 466 |
respiratory pathogens | 465 |
rna extraction | 465 |
host disease | 464 |
chronic gvhd | 461 |
clinical features | 459 |
sequence analysis | 459 |
central nervous | 458 |
staphylococcus aureus | 458 |
pcr product | 457 |
pg ml | 457 |
significantly increased | 455 |
pregnant women | 454 |
two different | 454 |
statistical analysis | 453 |
cell proliferation | 453 |
rna viruses | 453 |
author funder | 452 |
positive control | 452 |
granted medrxiv | 451 |
immune responses | 450 |
infectious bronchitis | 450 |
phylogenetic analysis | 449 |
closely related | 447 |
genomic dna | 446 |
virus isolation | 445 |
type i | 445 |
acute gvhd | 440 |
adverse events | 439 |
retrospective study | 439 |
agarose gel | 438 |
data suggest | 437 |
lung cancer | 434 |
median time | 433 |
blood bank | 433 |
infected patients | 433 |
room temperature | 433 |
oxidative stress | 433 |
virus detection | 431 |
respiratory symptoms | 431 |
clinical characteristics | 431 |
respiratory viral | 429 |
specific primers | 429 |
monoclonal antibodies | 429 |
smooth muscle | 428 |
food safety | 428 |
total rna | 426 |
widely used | 424 |
infected cells | 423 |
results showed | 422 |
risk factor | 421 |
diagnostic tests | 420 |
copyright holder | 419 |
side effects | 419 |
previously reported | 418 |
results indicate | 416 |
world health | 414 |
human coronavirus | 413 |
first time | 412 |
high sensitivity | 412 |
detection limit | 410 |
determine whether | 409 |
endothelial cells | 408 |
respiratory infection | 407 |
cell cultures | 405 |
generation sequencing | 405 |
clinical trials | 404 |
negative control | 403 |
acid amplification | 401 |
internal control | 401 |
hbv dna | 400 |
hong kong | 400 |
virus infections | 398 |
median follow | 397 |
case report | 397 |
pcr reaction | 397 |
tumor cells | 397 |
viral loads | 397 |
growth factor | 397 |
fecal samples | 397 |
wild type | 395 |
reference genes | 395 |
disease control | 394 |
safety authority | 394 |
chronic hepatitis | 393 |
adult patients | 393 |
tissue samples | 393 |
european food | 390 |
informed consent | 389 |
medical center | 388 |
gold standard | 388 |
commonly used | 388 |
design method | 388 |
health organization | 385 |
significantly different | 384 |
samples collected | 384 |
quantitative real | 382 |
amino acids | 382 |
renal failure | 381 |
health care | 381 |
version posted | 376 |
results finding | 375 |
study period | 374 |
respiratory illness | 374 |
multiplex real | 373 |
large number | 372 |
bronchitis virus | 371 |
differential diagnosis | 370 |
viral pathogens | 370 |
increased risk | 370 |
cancer cells | 366 |
highly sensitive | 366 |
young children | 364 |
free survival | 362 |
quality control | 362 |
expression levels | 361 |
cell surface | 360 |
systematic review | 360 |
clinical symptoms | 359 |
wide range | 359 |
care unit | 356 |
significant increase | 355 |
ct values | 354 |
cell types | 354 |
prostate cancer | 354 |
pandemic influenza | 353 |
pcr detection | 352 |
logistic regression | 351 |
respiratory specimens | 350 |
transfusion medicine | 349 |
cell death | 349 |
nk cells | 349 |
total number | 348 |
significantly reduced | 346 |
healthy controls | 346 |
false negative | 345 |
inflammatory response | 342 |
pcr analysis | 342 |
cord blood | 342 |
viral genome | 342 |
determined using | 341 |
human bocavirus | 341 |
patients undergoing | 340 |
allogeneic hematopoietic | 340 |
false positive | 338 |
year old | 337 |
hospitalized patients | 337 |
pediatric patients | 336 |
disease severity | 335 |
mononuclear cells | 334 |
monoclonal antibody | 334 |
days post | 334 |
acid extraction | 334 |
three patients | 332 |
time points | 332 |
platelet count | 331 |
respiratory samples | 329 |
molecular methods | 328 |
pacientes con | 327 |
specific antibodies | 326 |
nasopharyngeal swabs | 326 |
blood donor | 322 |
cell carcinoma | 322 |
sample preparation | 321 |
infectious agents | 321 |
cohort study | 321 |
lung disease | 320 |
cerebrospinal fluid | 319 |
pcr using | 319 |
situ hybridization | 318 |
recent years | 318 |
analyzed using | 317 |
porcine epidemic | 317 |
pcr system | 315 |
nasopharyngeal swab | 315 |
feline infectious | 314 |
infectious peritonitis | 313 |
symptom onset | 312 |
pcr positive | 312 |
results show | 311 |
predictive value | 311 |
one case | 311 |
primer pairs | 311 |
analysis revealed | 309 |
urinary tract | 309 |
clinical isolates | 309 |
cancer patients | 308 |
cell cycle | 306 |
prospective study | 306 |
los pacientes | 306 |
hcv rna | 306 |
patients receiving | 305 |
seasonal influenza | 305 |
gvhd prophylaxis | 303 |
analysis showed | 303 |
middle east | 303 |
patients treated | 303 |
parainfluenza virus | 303 |
clinical practice | 302 |
dendritic cells | 300 |
peer review | 300 |
clinical diagnosis | 300 |
kg day | 300 |
diarrhea virus | 299 |
spinal cord | 297 |
renal function | 297 |
clinical data | 297 |
pcr method | 296 |
complete remission | 294 |
results obtained | 294 |
detection methods | 293 |
high levels | 293 |
viral replication | 293 |
red cells | 293 |
streptococcus pneumoniae | 292 |
step rt | 292 |
recent studies | 292 |
significantly associated | 292 |
lung function | 292 |
porcine circovirus | 291 |
innate immune | 290 |
dengue virus | 289 |
lg ml | 289 |
conventional rt | 289 |
linked immunosorbent | 289 |
type ii | 289 |
described previously | 288 |
three different | 287 |
time quantitative | 287 |
sample collection | 286 |
molecular weight | 286 |
patients without | 285 |
iu ml | 285 |
immunosorbent assay | 285 |
clinical presentation | 284 |
pcr kit | 284 |
stool samples | 283 |
positive patients | 283 |
master mix | 283 |
made available | 282 |
long term | 282 |
mouse model | 281 |
detection rate | 281 |
disease virus | 280 |
diagnostic methods | 280 |
high prevalence | 279 |
blood cultures | 279 |
epidemic diarrhea | 278 |
plasma membrane | 278 |
measured using | 276 |
en pacientes | 275 |
transcription polymerase | 275 |
standard deviation | 275 |
mrna levels | 275 |
different types | 274 |
cfu ml | 274 |
two cases | 274 |
plasma samples | 273 |
multivariate analysis | 273 |
bronchoalveolar lavage | 272 |
genome sequence | 272 |
positive cells | 272 |
copies per | 271 |
lateral flow | 271 |
united kingdom | 270 |
antibiotic resistance | 270 |
within days | 269 |
cell count | 269 |
west nile | 269 |
findings suggest | 269 |
infection control | 269 |
analytical sensitivity | 268 |
ex vivo | 268 |
human rhinovirus | 268 |
syndrome virus | 267 |
age groups | 267 |
current study | 267 |
respiratory distress | 266 |
swab samples | 266 |
diagnostic accuracy | 266 |
also found | 265 |
diagnostic test | 265 |
statistical significance | 265 |
even though | 265 |
may contribute | 265 |
herpes simplex | 264 |
negative controls | 264 |
positive result | 264 |
clinical manifestations | 264 |
pseudomonas aeruginosa | 263 |
viral respiratory | 262 |
weight loss | 261 |
clinical course | 261 |
standard curve | 261 |
transplant recipients | 261 |
viral shedding | 259 |
clinical microbiology | 259 |
confirmed cases | 259 |
immunodeficiency virus | 259 |
western blotting | 257 |
molecular diagnostics | 257 |
also observed | 257 |
platelet concentrates | 256 |
severe disease | 256 |
may lead | 256 |
acid sequence | 256 |
study group | 255 |
cancer cell | 255 |
human respiratory | 255 |
rna polymerase | 255 |
serial dilutions | 254 |
per reaction | 254 |
allogeneic stem | 254 |
diabetes mellitus | 254 |
primer pair | 254 |
medrxiv preprint | 254 |
blood culture | 253 |
mortality rate | 253 |
molecular detection | 253 |
transcription factor | 253 |
bacterial infections | 253 |
among patients | 253 |
viral culture | 253 |
heart failure | 253 |
nitric oxide | 252 |
viral nucleic | 251 |
positive rt | 251 |
cd cell | 250 |
virus type | 250 |
developing countries | 250 |
blot analysis | 250 |
fever virus | 249 |
class i | 249 |
inflammatory cytokines | 249 |
nucleotide sequence | 248 |
age group | 248 |
data analysis | 248 |
clostridium difficile | 248 |
multiple myeloma | 248 |
dependent manner | 248 |
virus replication | 247 |
multiplex rt | 247 |
rapid diagnosis | 247 |
disease progression | 247 |
primer sets | 246 |
negative rt | 246 |
dna amplification | 246 |
clinical trial | 246 |
nasal swabs | 246 |
molecular biology | 245 |
immunocompromised patients | 245 |
transfusion reactions | 245 |
patients infected | 244 |
authors declare | 244 |
liver disease | 244 |
pcr reactions | 243 |
regression analysis | 243 |
several studies | 242 |
using real | 241 |
cell lymphoma | 241 |
pcr primers | 241 |
high throughput | 241 |
may play | 240 |
international license | 240 |
ct scan | 239 |
antibiotic therapy | 239 |
quantitative rt | 239 |
early diagnosis | 239 |
pulmonary disease | 239 |
four patients | 238 |
patient samples | 238 |
drug resistance | 238 |
sars coronavirus | 238 |
dna extraction | 237 |
ml min | 236 |
highly conserved | 236 |
differentially expressed | 236 |
nile virus | 236 |
spike protein | 235 |
high level | 235 |
reactive protein | 235 |
study showed | 235 |
coronavirus infection | 235 |
cell transplant | 235 |
positive cases | 233 |
taken together | 233 |
antigen detection | 232 |
mycoplasma pneumoniae | 232 |
conventional pcr | 231 |
last years | 231 |
digital pcr | 231 |
significantly decreased | 230 |
target dna | 229 |
molecular mechanisms | 229 |
viral particles | 229 |
blood stem | 228 |
stranded dna | 228 |
susceptibility testing | 228 |
dna sequencing | 228 |
fold increase | 227 |
clinically significant | 227 |
well tolerated | 226 |
negative samples | 226 |
graft versus | 226 |
genetic diversity | 226 |
ct findings | 224 |
complete genome | 224 |
samples tested | 224 |
tissue culture | 224 |
se recomienda | 224 |
computed tomography | 224 |
medical records | 223 |
unrelated donor | 223 |
next generation | 223 |
en los | 223 |
reverse primer | 222 |
detection system | 222 |
east respiratory | 221 |
old male | 221 |
ct value | 221 |
causative agent | 220 |
molecular diagnosis | 220 |
may provide | 220 |
old female | 220 |
one year | 219 |
primer set | 219 |
clinically relevant | 219 |
per year | 219 |
laboratory diagnosis | 218 |
target genes | 218 |
analysis using | 218 |
new york | 218 |
data indicate | 217 |
using pcr | 217 |
enteric viruses | 217 |
transgenic mice | 217 |
may occur | 217 |
swine fever | 217 |
within hours | 216 |
gestational age | 216 |
single nucleotide | 216 |
rights reserved | 216 |
five patients | 216 |
confidence interval | 215 |
allogeneic hsct | 215 |
early detection | 215 |
bacterial infection | 215 |
target sequence | 215 |
blood banks | 214 |
positive controls | 214 |
critically ill | 214 |
simplex virus | 213 |
age years | 213 |
nucleotide sequences | 213 |
gastrointestinal tract | 212 |
sensitive detection | 212 |
stranded rna | 212 |
feline coronavirus | 212 |
high dose | 211 |
diagnostic testing | 211 |
retrospective analysis | 211 |
rna virus | 210 |
genbank accession | 210 |
protein levels | 210 |
pathogen detection | 209 |
copy numbers | 209 |
transfusion service | 209 |
preliminary results | 209 |
graft failure | 209 |
viral dna | 208 |
antibody response | 208 |
sanger sequencing | 208 |
classical swine | 208 |
bacterial pathogens | 208 |
curve analysis | 208 |
small number | 207 |
versus host | 207 |
hospitalized children | 207 |
adverse effects | 207 |
molecular characterization | 206 |
positive rate | 206 |
cumulative incidence | 206 |
canine parvovirus | 206 |
myeloid leukemia | 205 |
extracellular matrix | 205 |
time polymerase | 205 |
chlamydia pneumoniae | 204 |
results demonstrate | 204 |
serum levels | 204 |
hepatocellular carcinoma | 204 |
blood collection | 204 |
blood donations | 204 |
previous study | 204 |
con covid | 204 |
antibiotic treatment | 203 |
two weeks | 202 |
low levels | 202 |
sequence data | 202 |
drinking water | 201 |
physical examination | 201 |
renal disease | 201 |
tested using | 200 |
patients showed | 200 |
cell activation | 200 |
squamous cell | 200 |
tested negative | 200 |
genome sequencing | 200 |
acid detection | 199 |
transport medium | 199 |
study population | 199 |
faecal samples | 199 |
based assays | 199 |
based detection | 199 |
antibody responses | 199 |
time point | 198 |
mini kit | 198 |
free water | 197 |
human coronaviruses | 197 |
also used | 197 |
kidney disease | 197 |
blood supply | 196 |
reaction mixture | 196 |
antimicrobial resistance | 196 |
assessed using | 196 |
significant reduction | 196 |
laboratory tests | 196 |
based methods | 196 |
diagnostic tool | 196 |
molecular diagnostic | 195 |
clinical outcome | 195 |
general population | 195 |
cmv reactivation | 195 |
high specificity | 195 |
bovine serum | 195 |
pcr methods | 195 |
highly pathogenic | 195 |
conclusions reached | 194 |
autologous stem | 194 |
three times | 194 |
authority reserves | 194 |
issues addressed | 194 |
sample size | 193 |
nephrotic syndrome | 193 |
output adopted | 193 |
may cause | 193 |
awarded following | 193 |
colorectal cancer | 193 |
transparency principle | 193 |
also detected | 193 |
recent study | 193 |
published complying | 193 |
tender procedure | 193 |
lung tissue | 192 |
inclusion criteria | 192 |
healthy donors | 192 |
igg antibodies | 191 |
sputum samples | 191 |
cdna synthesis | 191 |
calculated using | 191 |
throat swabs | 191 |
multiple sclerosis | 191 |
north america | 191 |
human immunodeficiency | 191 |
specific pcr | 190 |
may result | 190 |
acute myeloid | 189 |
turnaround time | 189 |
one hundred | 189 |
study aimed | 189 |
deficient mice | 188 |
healthy dogs | 188 |
porcine reproductive | 188 |
control subjects | 187 |
significant correlation | 187 |
resistance genes | 187 |
cell responses | 187 |
small intestine | 187 |
evaluated using | 187 |
future studies | 187 |
plasmid dna | 187 |
blood units | 186 |
immune cells | 186 |
expression level | 186 |
host cell | 186 |
without prejudice | 186 |
emergency department | 186 |
healthcare workers | 186 |
bodies identified | 185 |
currently available | 185 |
molecular testing | 185 |
vero cells | 184 |
patients developed | 184 |
genome sequences | 184 |
naturally occurring | 184 |
incubation period | 183 |
cell viability | 183 |
positive pcr | 183 |
viral diseases | 183 |
sequence alignment | 183 |
low viral | 183 |
year period | 183 |
grade ii | 182 |
family members | 182 |
early stage | 182 |
assay using | 182 |
national institute | 182 |
parainfluenza viruses | 182 |
gene sequences | 181 |
clinical outcomes | 181 |
per day | 181 |
white blood | 181 |
blood center | 180 |
positive correlation | 180 |
experimentally infected | 180 |
myeloablative conditioning | 180 |
like particles | 180 |
molecular epidemiology | 180 |
viral detection | 180 |
control groups | 179 |
strains isolated | 179 |
exact test | 179 |
old woman | 178 |
nested rt | 178 |
realtime pcr | 178 |
sore throat | 178 |
canine distemper | 178 |
molecular assays | 178 |
control measures | 177 |
animal models | 177 |
rrna gene | 177 |
lamp assay | 177 |
data show | 177 |
consecutive patients | 177 |
also showed | 177 |
factors associated | 176 |
clinical laboratory | 176 |
marrow transplantation | 175 |
specific antibody | 175 |
test result | 175 |
clinical disease | 175 |
chronic obstructive | 175 |
study included | 175 |
positive test | 174 |
significant decrease | 174 |
nasopharyngeal aspirates | 174 |
may represent | 174 |
reference standard | 174 |
epithelial cell | 174 |
circovirus type | 174 |
similar results | 174 |
barr virus | 173 |
antimicrobial susceptibility | 173 |
group i | 173 |
ill patients | 173 |
first step | 173 |
growth factors | 172 |
infected individuals | 172 |
transmission electron | 172 |
common cold | 172 |
swab specimens | 171 |
see table | 171 |
three groups | 171 |
relatively high | 171 |
control study | 171 |
virus rna | 170 |
detected using | 170 |
virus strains | 170 |
transmissible gastroenteritis | 170 |
grade iii | 170 |
positive specimens | 170 |
may help | 170 |
one study | 170 |
life technologies | 170 |
pilot study | 170 |
respiratory failure | 169 |
clinical studies | 169 |
laboratory testing | 169 |
ethics committee | 169 |
open reading | 169 |
acute phase | 168 |
influenza vaccine | 168 |
samples using | 168 |
tract disease | 168 |
linear regression | 168 |
rapid identification | 168 |
whole genome | 168 |
abdominal pain | 168 |
obstructive pulmonary | 168 |
serological tests | 168 |
amplification assay | 168 |
broad spectrum | 168 |
thermal cycler | 167 |
higher risk | 167 |
six patients | 167 |
transcription factors | 167 |
molecular techniques | 167 |
viral genomes | 167 |
based assay | 167 |
clinical laboratories | 167 |
samples obtained | 167 |
related mortality | 167 |
relatively low | 166 |
fold higher | 166 |
new zealand | 166 |
also tested | 165 |
mechanical ventilation | 165 |
culture medium | 165 |
signal transduction | 165 |
gene therapy | 165 |
major cause | 165 |
structural proteins | 165 |
high mortality | 164 |
final extension | 164 |
resistant strains | 164 |
per patient | 164 |
univariate analysis | 164 |
blood flow | 163 |
times higher | 163 |
transcriptase polymerase | 163 |
clinical significance | 163 |
cell counts | 163 |
nk cell | 163 |
swine influenza | 163 |
forward primer | 163 |
two years | 163 |
newcastle disease | 163 |
antibody titers | 163 |
confirmed covid | 163 |
higher sensitivity | 162 |
significant association | 162 |
higher levels | 162 |
vaccine strain | 162 |
cytopathic effect | 162 |
specific detection | 162 |
binding sites | 162 |
patients died | 162 |
highly specific | 162 |
culture media | 162 |
urine samples | 161 |
high viral | 161 |
hospital admission | 160 |
previously published | 160 |
direct contact | 160 |
well known | 160 |
another study | 160 |
plant mirnas | 160 |
cytokine production | 160 |
human influenza | 160 |
binding protein | 159 |
factor viii | 159 |
among children | 159 |
using different | 159 |
phylogenetic tree | 159 |
green i | 159 |
blood product | 159 |
least two | 159 |
one sample | 159 |
false positives | 159 |
reduced intensity | 159 |
months post | 159 |
response rate | 158 |
host cells | 158 |
hcv infection | 158 |
human adenovirus | 158 |
first report | 158 |
blood mononuclear | 158 |
healthy volunteers | 158 |
dna damage | 158 |
high frequency | 158 |
hbv infection | 158 |
fungal infections | 157 |
like illness | 157 |
bacterial contamination | 157 |
amplification products | 156 |
heart rate | 156 |
distress syndrome | 156 |
thermal cycling | 156 |
viral transport | 156 |
umbilical cord | 156 |
poor prognosis | 156 |
three cases | 156 |
based amplification | 156 |
mesenchymal stem | 156 |
serum creatinine | 156 |
also known | 156 |
risk assessment | 156 |
detection rates | 156 |
hepatitis virus | 155 |
para el | 155 |
platelet counts | 155 |
patients underwent | 155 |
copies reaction | 155 |
canine coronavirus | 155 |
better understanding | 155 |
using primers | 155 |
increased expression | 155 |
antibody test | 155 |
also performed | 155 |
using two | 155 |
conventional methods | 155 |
blood safety | 155 |
mast cells | 154 |
heart disease | 154 |
fully automated | 154 |
disease caused | 154 |
serum albumin | 154 |
signaling pathways | 154 |
genomic rna | 154 |
blood loss | 153 |
general hospital | 153 |
reactive oxygen | 153 |
rna extracted | 153 |
pcr result | 152 |
transcriptase pcr | 152 |
thermo fisher | 152 |
donor chimerism | 152 |
day post | 152 |
naturally infected | 152 |
target gene | 152 |
negative predictive | 152 |
diagnostic tools | 151 |
detection method | 151 |
obtained using | 151 |
hematopoietic cell | 151 |
necrosis factor | 151 |
mdck cells | 151 |
multiplex reverse | 150 |
recombinase polymerase | 150 |
virus particles | 150 |
throat swab | 150 |
mycobacterium tuberculosis | 150 |
supplementary table | 150 |
specific primer | 150 |
patient care | 150 |
leading cause | 150 |
distemper virus | 150 |
using rt | 150 |
experimental infection | 150 |
suspected cases | 150 |
polymerase amplification | 149 |
patients admitted | 149 |
randomly selected | 149 |
four different | 149 |
amplified using | 149 |
cell type | 149 |
body mass | 149 |
matched unrelated | 148 |
healthy cats | 148 |
protein kinase | 148 |
class ii | 148 |
studies showed | 148 |
first case | 148 |
human serum | 148 |
healthy individuals | 148 |
suspected covid | 148 |
animal health | 147 |
infectious virus | 147 |
purified using | 147 |
design methods | 147 |
cd expression | 147 |
key role | 147 |
derived evs | 147 |
viral pneumonia | 147 |
intensity conditioning | 147 |
pcr amplicons | 147 |
laser desorption | 147 |
old man | 146 |
eight patients | 146 |
much higher | 146 |
cells expressing | 146 |
leukemia virus | 146 |
antibody detection | 146 |
signaling pathway | 146 |
limited number | 146 |
oxygen species | 145 |
birth weight | 145 |
virus culture | 145 |
high incidence | 145 |
results findings | 145 |
expression analysis | 145 |
primers used | 145 |
seven patients | 145 |
rabies virus | 144 |
extracted using | 144 |
replacement therapy | 144 |
soft tissue | 144 |
large numbers | 144 |
infected mice | 144 |
conditioning regimens | 144 |
con el | 144 |
total protein | 144 |
antimicrobial agents | 144 |
genetic analysis | 144 |
nanoparticle tracking | 144 |
buffered saline | 144 |
rapid diagnostic | 144 |
single cell | 144 |
ethidium bromide | 144 |
coronavirus infections | 143 |
immunofluorescence assay | 143 |
severe respiratory | 143 |
normal range | 143 |
reverse primers | 143 |
coronavirus hku | 143 |
patients presented | 143 |
tissue sections | 142 |
group ii | 142 |
analysed using | 142 |
time period | 142 |
showed significant | 142 |
virus isolates | 142 |
capillary electrophoresis | 142 |
tcid ml | 141 |
water samples | 141 |
animal model | 141 |
genes involved | 141 |
fisher scientific | 141 |
accession number | 141 |
crucial role | 141 |
median number | 141 |
observational study | 141 |
binding site | 141 |
human plasma | 141 |
rna copies | 141 |
amplifi cation | 140 |
negative patients | 140 |
blood vessels | 140 |
serially diluted | 140 |
tracking analysis | 140 |
acute leukemia | 140 |
cycling conditions | 140 |
common respiratory | 140 |
preliminary data | 140 |
melting curve | 140 |
done using | 140 |
protein gene | 140 |
medical university | 139 |
based real | 139 |
el uso | 139 |
statistical analyses | 139 |
diagnostic assays | 139 |
patients aged | 139 |
dna sequence | 139 |
respiratory diseases | 139 |
patients may | 139 |
endothelial cell | 139 |
transcription pcr | 139 |
antibiotic use | 139 |
previously shown | 138 |
tritrichomonas foetus | 138 |
lung injury | 138 |
progenitor cells | 138 |
children aged | 138 |
reaction assay | 137 |
nine patients | 137 |
severe covid | 137 |
controlled trial | 137 |
immunohistochemical staining | 137 |
final concentration | 137 |
extraction kit | 137 |
vaccine strains | 137 |
muscle cells | 137 |
positive blood | 137 |
quantitative detection | 137 |
proinflammatory cytokines | 137 |
positive predictive | 136 |
acid sequences | 136 |
data collection | 136 |
epidemiological studies | 136 |
early stages | 136 |
plasma cells | 136 |
stromal cells | 136 |
rrt pcr | 136 |
zika virus | 136 |
th day | 136 |
ovarian cancer | 135 |
university medical | 135 |
effective treatment | 135 |
included patients | 135 |
pulmonary function | 135 |
hospital stay | 135 |
human rhinoviruses | 135 |
first days | 135 |
cell receptor | 135 |
genes encoding | 135 |
negative bacteria | 135 |
studies using | 135 |
hematological malignancies | 135 |
study shows | 134 |
fatty acid | 134 |
orf ab | 134 |
month period | 134 |
left ventricular | 134 |
disease status | 134 |
antiviral therapy | 134 |
emerging infectious | 134 |
igm antibodies | 134 |
airway epithelial | 134 |
years ago | 133 |
cells showed | 133 |
symptomatic patients | 133 |
infected cats | 133 |
insulin resistance | 133 |
mixed infections | 133 |
converting enzyme | 133 |
dna samples | 133 |
van een | 133 |
patients diagnosed | 133 |
veterinary medicine | 133 |
per sample | 133 |
poorly understood | 132 |
enzyme immunoassay | 132 |
rbc units | 132 |
older adults | 132 |
reference gene | 132 |
ms ms | 131 |
pfu ml | 131 |
adenovirus type | 131 |
blood services | 131 |
foster city | 131 |
fatty acids | 131 |
better understand | 131 |
fusion protein | 131 |
igg antibody | 131 |
first study | 131 |
odds ratio | 131 |
treated cells | 131 |
liver biopsy | 131 |
protein level | 131 |
sickle cell | 131 |
nasal swab | 130 |
aged years | 130 |
ca i | 130 |
transcription loop | 130 |
results indicated | 130 |
helicobacter pylori | 130 |
well established | 130 |
mouth disease | 130 |
healthy subjects | 130 |
case series | 130 |
skeletal muscle | 130 |
gene encoding | 130 |
neutralizing antibodies | 130 |
autologous blood | 130 |
specific cd | 130 |
new coronavirus | 129 |
low level | 129 |
transplant patients | 129 |
care testing | 129 |
higher prevalence | 129 |
first year | 129 |
dna sequences | 129 |
cell growth | 129 |
methods used | 128 |
ebola virus | 128 |
cell source | 128 |
transfusion services | 128 |
antigen test | 128 |
dna microarray | 128 |
exome sequencing | 128 |
high resolution | 128 |
clinical management | 128 |
dna viruses | 128 |
south korea | 128 |
survival rate | 127 |
institutional review | 127 |
hiv infection | 127 |
adverse reactions | 127 |
pcr master | 127 |
cycle threshold | 127 |
data obtained | 127 |
prognostic factors | 127 |
bovine respiratory | 127 |
months later | 127 |
innate immunity | 127 |
tumor necrosis | 127 |
clinical use | 126 |
liquid chromatography | 126 |
remains unclear | 126 |
european countries | 126 |
common cause | 126 |
high affinity | 126 |
gene sequence | 126 |
roche diagnostics | 126 |
cells using | 126 |
control samples | 126 |
patients presenting | 126 |
method using | 126 |
tumour cells | 126 |
previous reports | 126 |
showed high | 126 |
patient management | 125 |
conserved regions | 125 |
accession numbers | 125 |
low dose | 125 |
del paciente | 125 |
clinical evaluation | 125 |
nucleocapsid protein | 125 |
fresh frozen | 125 |
primer design | 125 |
family history | 125 |
south africa | 125 |
bovine coronavirus | 125 |
written informed | 125 |
inflammatory responses | 125 |
reference laboratory | 125 |
high degree | 125 |
gold nanoparticles | 125 |
review board | 125 |
probe sets | 124 |
using specific | 124 |
cardiovascular disease | 124 |
gastroenteritis virus | 124 |
primer probe | 124 |
well plates | 124 |
severe cases | 124 |
inflammatory bowel | 124 |
randomized controlled | 124 |
will help | 124 |
viral antigen | 124 |
plasma levels | 124 |
detection limits | 124 |
past years | 124 |
healthy children | 124 |
direct detection | 124 |
gene mutations | 124 |
acid testing | 123 |
correlation coefficient | 123 |
detection kit | 123 |
frozen plasma | 123 |
unrelated donors | 123 |
significant changes | 123 |
regression model | 123 |
mortality rates | 123 |
patient died | 123 |
relapse mortality | 123 |
reuse allowed | 123 |
inhibitory effect | 123 |
potential role | 123 |
bronchial epithelial | 123 |
specimens collected | 123 |
infectious complications | 123 |
deep sequencing | 123 |
colon cancer | 123 |
surface expression | 123 |
antibody tests | 123 |
investigate whether | 123 |
viral sequences | 123 |
viruses using | 123 |
acute renal | 123 |
cell adhesion | 123 |
without permission | 123 |
allowed without | 123 |
qpcr assay | 123 |
blood component | 122 |
renal biopsy | 122 |
national health | 122 |
accurate diagnosis | 122 |
microscopic examination | 122 |
children hospitalized | 122 |
nucleotide polymorphisms | 122 |
critical role | 122 |
median duration | 122 |
final volume | 122 |
flow cytometric | 122 |
tyrosine kinase | 122 |
autosomal recessive | 122 |
acute lymphoblastic | 122 |
hodgkin lymphoma | 121 |
definitive diagnosis | 121 |
autoimmune diseases | 121 |
rapid antigen | 121 |
type diabetes | 121 |
pcr based | 121 |
process control | 121 |
virus strain | 121 |
study demonstrates | 121 |
mouse hepatitis | 121 |
pcr negative | 121 |
coronavirus pneumonia | 121 |
reading frame | 121 |
mass index | 121 |
fragment length | 121 |
clinical relevance | 121 |
reference strains | 121 |
restriction enzyme | 121 |
amniotic fluid | 121 |
wound healing | 120 |
diagnostic performance | 120 |
rna detection | 120 |
human papillomavirus | 120 |
ct scans | 120 |
alkaline phosphatase | 120 |
low sensitivity | 120 |
medical history | 120 |
magnetic beads | 120 |
throughput sequencing | 120 |
primer sequences | 120 |
otitis media | 120 |
compared using | 120 |
rna isolation | 120 |
infl uenza | 120 |
dna fragments | 119 |
quality assurance | 119 |
patient population | 119 |
useful tool | 119 |
desorption ionization | 119 |
antibody screening | 119 |
body fluids | 119 |
klebsiella pneumoniae | 119 |
red cross | 119 |
negative result | 118 |
donor selection | 118 |
using standard | 118 |
infections caused | 118 |
blood volume | 118 |
candidate genes | 118 |
less sensitive | 118 |
will provide | 118 |
supplementary material | 118 |
nanotrap particles | 118 |
enzyme activity | 118 |
two methods | 118 |
performed according | 118 |
high rate | 118 |
competing interests | 118 |
sequence identity | 118 |
single center | 118 |
clinical setting | 117 |
dose chemotherapy | 117 |
frequently used | 117 |
one week | 117 |
conducted using | 117 |
combination therapy | 117 |
cell dose | 117 |
patient received | 117 |
antimicrobial therapy | 117 |
lymphoblastic leukemia | 117 |
amplified products | 117 |
adipose tissue | 117 |
direct sequencing | 117 |
molecular analysis | 117 |
data demonstrate | 116 |
protective equipment | 116 |
cells may | 116 |
per ml | 116 |
sin embargo | 116 |
frequently detected | 116 |
acute gastroenteritis | 116 |
blood sample | 116 |
samples showed | 116 |
national blood | 116 |
sequencing data | 116 |
chronic inflammation | 116 |
increased levels | 115 |
underlying disease | 115 |
bowel disease | 115 |
glial cells | 115 |
laboratory mice | 115 |
abi prism | 115 |
extraction methods | 115 |
three months | 115 |
amplification method | 115 |
specific rt | 115 |
cd ra | 115 |
diagnostic sensitivity | 115 |
avian infectious | 115 |
por covid | 115 |
inflammatory cells | 115 |
time course | 115 |
penaeus monodon | 115 |
large scale | 114 |
like receptor | 114 |
considered significant | 114 |
lavage fluid | 114 |
chronic renal | 114 |
coding region | 114 |
cd positive | 114 |
dna methylation | 114 |
square test | 114 |
elderly patients | 114 |
considered positive | 114 |
risk patients | 114 |
teaching hospital | 114 |
detection using | 114 |
bl mice | 114 |
increased significantly | 113 |
sensitive method | 113 |
treated patients | 113 |
mouse models | 113 |
endoplasmic reticulum | 113 |
amplification efficiency | 113 |
research institute | 113 |
may affect | 113 |
antiviral drugs | 113 |
possible role | 113 |
retrospectively analyzed | 113 |
additional file | 113 |
lysis buffer | 113 |
antiglobulin test | 113 |
patient developed | 113 |
literature review | 113 |
virus dna | 113 |
molecular tests | 113 |
target cells | 113 |
cmv infection | 113 |
false negatives | 113 |
patients suffering | 112 |
blood service | 112 |
septic shock | 112 |
target sequences | 112 |
viruses detected | 112 |
cell membrane | 112 |
age range | 112 |
will allow | 112 |
platelet engraftment | 112 |
vitro activity | 112 |
antiviral treatment | 112 |
identified using | 112 |
confocal microscopy | 112 |
taqman probe | 112 |
acute graft | 112 |
laboratory data | 112 |
housekeeping genes | 112 |
mhc class | 112 |
six months | 112 |
also included | 112 |
grade i | 112 |
will also | 111 |
recent advances | 111 |
different time | 111 |
brain tissue | 111 |
mg day | 111 |
reaction volume | 111 |
reverse transcribed | 111 |
high grade | 111 |
lactate dehydrogenase | 111 |
year os | 111 |
infected animals | 111 |
time consuming | 111 |
standard curves | 111 |
assisted laser | 111 |
two major | 111 |
older patients | 111 |
wide variety | 111 |
viral etiology | 111 |
one step | 111 |
en un | 110 |
immunosuppressive therapy | 110 |
diagnostic laboratories | 110 |
encephalitis virus | 110 |
receptor binding | 110 |
drug administration | 110 |
diagnostic techniques | 110 |
first line | 110 |
complete response | 110 |
different methods | 110 |
se ha | 110 |
economic losses | 110 |
specimen collection | 110 |
viral antigens | 110 |
days later | 110 |
czech republic | 110 |
new england | 109 |
blood centers | 109 |
patients compared | 109 |
coronavirus nl | 109 |
culture supernatants | 109 |
diagnostic value | 109 |
study suggests | 109 |
knockout mice | 109 |
microarray analysis | 109 |
domestic cats | 109 |
platelet transfusion | 109 |
respiratory coronavirus | 109 |
primary immunodeficiency | 109 |
serological testing | 109 |
human health | 109 |
uric acid | 109 |
fluorescence intensity | 109 |
examination revealed | 109 |
ko mice | 109 |
immune reconstitution | 109 |
personal protective | 108 |
vascular endothelial | 108 |
consecutive days | 108 |
environmental samples | 108 |
tumor cell | 108 |
pcr inhibitors | 108 |
mycophenolate mofetil | 108 |
reported cases | 108 |
different concentrations | 108 |
rna molecules | 108 |
liver cirrhosis | 108 |
antibody testing | 108 |
cell function | 108 |
log copies | 108 |
length polymorphism | 108 |
melting temperature | 108 |
corona virus | 108 |
total nucleic | 108 |
group compared | 108 |
microbiology laboratory | 108 |
low risk | 108 |
yellow head | 108 |
coronavirus associated | 108 |
clinical findings | 107 |
pathogenic avian | 107 |
one month | 107 |
histological examination | 107 |
kg body | 107 |
north american | 107 |
cell therapy | 107 |
magnetic resonance | 107 |
multiple sequence | 107 |
short time | 107 |
infection may | 107 |
takes place | 107 |
exogenous ncrnas | 107 |
dynamic range | 107 |
human herpesvirus | 107 |
serologic testing | 107 |
human genome | 107 |
pcr primer | 107 |
transport media | 107 |
secondary structure | 107 |
different species | 106 |
duplex real | 106 |
ml kg | 106 |
clinical information | 106 |
neutrophil engraftment | 106 |
asthma exacerbation | 106 |
aml patients | 106 |
extremely rare | 106 |
many patients | 106 |
rbc transfusion | 106 |
asthma exacerbations | 106 |
may reflect | 106 |
expression profiles | 106 |
aplastic anemia | 106 |
respiratory pathogen | 106 |
full length | 106 |
diagnostic laboratory | 106 |
light microscopy | 106 |
increasing number | 106 |
three days | 106 |
total volume | 106 |
buffy coat | 106 |
first two | 106 |
natural killer | 106 |
scoring system | 106 |
positive sample | 105 |
oropharyngeal swabs | 105 |
fungal infection | 105 |
many cases | 105 |
cell differentiation | 105 |
confidence intervals | 105 |
inflammatory cytokine | 105 |
laboratory findings | 105 |
rna sequencing | 105 |
higher incidence | 105 |
virus genome | 105 |
el paciente | 105 |
major role | 105 |
culture supernatant | 105 |
antigen tests | 105 |
two samples | 105 |
dilution series | 105 |
treatment group | 105 |
expression pattern | 105 |
phylogenetic trees | 105 |
extracted rna | 105 |
clinical sensitivity | 105 |
differential expression | 105 |
virus transmission | 105 |
different cell | 105 |
taq dna | 105 |
life cycle | 105 |
bovine viral | 105 |
tertiary care | 104 |
acute infection | 104 |
many studies | 104 |
control cells | 104 |
signalling pathways | 104 |
retrospective cohort | 104 |
probably due | 104 |
porcine respiratory | 104 |
gi tract | 104 |
protective effect | 104 |
vast majority | 104 |
close contact | 104 |
sars patients | 104 |
samples taken | 104 |
influenza infection | 104 |
likely due | 104 |
th percentile | 104 |
isolated using | 103 |
many countries | 103 |
well plate | 103 |
serological assays | 103 |
wt mice | 103 |
laboratory animal | 103 |
cov infection | 103 |
allowed us | 103 |
survival rates | 103 |
paraffin embedded | 103 |
bacterial species | 103 |
skin lesions | 103 |
haemophilus influenzae | 103 |
amplification reaction | 103 |
vitro studies | 103 |
using flow | 103 |
dna microarrays | 102 |
immunohistochemical analysis | 102 |
many different | 102 |
small cell | 102 |
san diego | 102 |
raw sewage | 102 |
cells infected | 102 |
blood count | 102 |
samples positive | 102 |
convalescent plasma | 102 |
liver injury | 102 |
two days | 102 |
significantly correlated | 102 |
host immune | 102 |
por el | 102 |
rna genome | 102 |
microglial cells | 102 |
genome copies | 102 |
invasive fungal | 102 |
covid pos | 102 |
studies suggest | 101 |
blood groups | 101 |
membrane protein | 101 |
nkt cells | 101 |
rna samples | 101 |
pcr conditions | 101 |
antiviral activity | 101 |
haematopoietic stem | 101 |
mammalian cells | 101 |
liver fibrosis | 101 |
two distinct | 101 |
clinical sample | 101 |
resistant staphylococcus | 101 |
also reported | 101 |
important cause | 101 |
consensus sequence | 101 |
persistent infection | 101 |
breast milk | 101 |
reaction mix | 101 |
initial denaturation | 101 |
pet birds | 101 |
studies will | 101 |
specific dna | 101 |
matched sibling | 101 |
fold dilutions | 100 |
influenza pandemic | 100 |
brain barrier | 100 |
body temperature | 100 |
experimental conditions | 100 |
annealing temperature | 100 |
biological samples | 100 |
inflammatory diseases | 100 |
table shows | 100 |
study using | 100 |
may explain | 100 |
infection among | 100 |
dna rna | 100 |
nucleotide identity | 100 |
renal transplantation | 100 |
global health | 100 |
recently described | 100 |
biopsy specimens | 100 |
post transplant | 100 |
genetic material | 100 |
stool specimens | 100 |
small rna | 100 |
van het | 100 |
human disease | 100 |
infect dis | 100 |
samples containing | 100 |
hemolytic anemia | 100 |
may serve | 100 |
gene segments | 99 |
mitral valve | 99 |
expression patterns | 99 |
ms phage | 99 |
coronavirus oc | 99 |
diagnostic criteria | 99 |
healthy control | 99 |
green real | 99 |
acute lower | 99 |
two viruses | 99 |
cardiac surgery | 99 |
genetic variation | 99 |
broad range | 99 |
chronic kidney | 99 |
high quality | 99 |
assays using | 99 |
capsid protein | 99 |
routine use | 99 |
marrow transplant | 99 |
study also | 99 |
viral proteins | 99 |
species identification | 99 |
protein concentration | 99 |
low grade | 99 |
cultured cells | 98 |
pulmonary fibrosis | 98 |
average age | 98 |
threshold cycle | 98 |
single dose | 98 |
quantitative reverse | 98 |
taq polymerase | 98 |
severe pneumonia | 98 |
infection rate | 98 |
white matter | 98 |
culture system | 98 |
among others | 98 |
weight gain | 98 |
highly expressed | 98 |
cell disease | 98 |
airway inflammation | 98 |
pathogenic bacteria | 98 |
gene rrt | 98 |
phase i | 98 |
quantitative analysis | 98 |
financial support | 98 |
liver tissue | 98 |
strand displacement | 98 |
purification kit | 98 |
young adults | 98 |
significant effect | 98 |
saudi arabia | 97 |
low cost | 97 |
cell wall | 97 |
human infection | 97 |
internal controls | 97 |
influenza surveillance | 97 |
liver transplantation | 97 |
also significantly | 97 |
case reports | 97 |
hela cells | 97 |
care workers | 97 |
vertical transmission | 97 |
oral administration | 97 |
investigated whether | 97 |
screening test | 97 |
clinical performance | 97 |
chronic inflammatory | 97 |
bij een | 97 |
feline leukemia | 97 |
newly diagnosed | 96 |
significantly improved | 96 |
restriction fragment | 96 |
rna mini | 96 |
infected cell | 96 |
vp gene | 96 |
influenza season | 96 |
significant improvement | 96 |
significantly less | 96 |
clinical impact | 96 |
virus types | 96 |
sars cov | 96 |
national university | 96 |
highly contagious | 96 |
generated using | 96 |
newly discovered | 96 |
respiratory secretions | 96 |
tract samples | 96 |
old boy | 96 |
ct imaging | 96 |
detect sars | 95 |
blood glucose | 95 |
cells kg | 95 |
mm tris | 95 |
rheumatoid arthritis | 95 |
university school | 95 |
one day | 95 |
dependent rna | 95 |
superscript iii | 95 |
health problem | 95 |
patients hospitalized | 95 |
mean value | 95 |
multiplex assays | 95 |
platelet aggregation | 95 |
contact tracing | 95 |
progressive disease | 95 |
pcr protocol | 95 |
detection assay | 95 |
fluid samples | 94 |
present work | 94 |
liver function | 94 |
met een | 94 |
lupus erythematosus | 94 |
neoplastic cells | 94 |
published data | 94 |
amplification methods | 94 |
glomerular filtration | 94 |
viruses isolated | 94 |
trend towards | 94 |
sectional study | 94 |
also evaluated | 94 |
genetic variants | 94 |
stage renal | 94 |
human cells | 94 |
quantified using | 94 |
partial response | 94 |
mast cell | 94 |
breast carcinoma | 94 |
expressed genes | 94 |
risk group | 94 |
remains unknown | 94 |
different regions | 94 |
van der | 94 |
activated protein | 94 |
asymptomatic patients | 94 |
exclusion criteria | 93 |
bp fragment | 93 |
retrospective review | 93 |
mcg ml | 93 |
year overall | 93 |
hek cells | 93 |
study provides | 93 |
developed countries | 93 |
point mutations | 93 |
routine laboratory | 93 |
five years | 93 |
may influence | 93 |
three years | 93 |
head virus | 93 |
cell migration | 93 |
hours post | 93 |
also identified | 93 |
patients transplanted | 93 |
viral isolation | 93 |
much lower | 93 |
different stages | 93 |
nasopharyngeal aspirate | 93 |
viral pathogen | 93 |
patients whose | 93 |
pneumocystis jirovecii | 93 |
mm mgcl | 92 |
quality assessment | 92 |
within min | 92 |
surface antigen | 92 |
exclusion chromatography | 92 |
toxoplasma gondii | 92 |
coat protein | 92 |
findings indicate | 92 |
prognostic factor | 92 |
viral disease | 92 |
study aims | 92 |
provide evidence | 92 |
bacillus anthracis | 92 |
conserved region | 92 |
human parainfluenza | 92 |
significantly greater | 92 |
platelet activation | 92 |
weeks gestation | 92 |
information regarding | 92 |
negative correlation | 92 |
posted june | 92 |
low prevalence | 92 |
treated mice | 92 |
species level | 92 |
iron deficiency | 92 |
gene amplification | 92 |
heat shock | 92 |
data collected | 92 |
cell populations | 92 |
immunodeficient mice | 92 |
binding proteins | 92 |
elevated levels | 92 |
phylogenetic analyses | 92 |
potential risk | 92 |
fold serial | 92 |
amplification tests | 91 |
routine clinical | 91 |
diffuse large | 91 |
multicenter study | 91 |
recipient cells | 91 |
two consecutive | 91 |
survival time | 91 |
hubei province | 91 |
viral agents | 91 |
dna levels | 91 |
early phase | 91 |
cell lysates | 91 |
chlamydia trachomatis | 91 |
antigen expression | 91 |
natural history | 91 |
using multiplex | 91 |
amplification techniques | 91 |
coronavirus rna | 91 |
type mice | 91 |
differ significantly | 91 |
twice daily | 91 |
four cases | 91 |
reverse genetics | 91 |
expression profile | 91 |
based pcr | 91 |
surveillance system | 91 |
inflammatory mediators | 91 |
japanese encephalitis | 90 |
negative test | 90 |
polymerase gene | 90 |
cell subsets | 90 |
bal fluid | 90 |
two independent | 90 |
first months | 90 |
first reported | 90 |
recently developed | 90 |
two strains | 90 |
surface area | 90 |
solid organ | 90 |
antibiotic susceptibility | 90 |
hematologic malignancies | 90 |
complete blood | 90 |
sibling donor | 90 |
recombinant proteins | 90 |
myocardial infarction | 90 |
virulence factors | 90 |
descriptive study | 90 |
function tests | 90 |
fluorescence signal | 90 |
results may | 90 |
liver failure | 90 |
mechanisms underlying | 90 |
disk diffusion | 89 |
ct features | 89 |
cycle sequencing | 89 |
currently used | 89 |
colloidal gold | 89 |
disease free | 89 |
prospective studies | 89 |
pcr technique | 89 |
cell lung | 89 |
time detection | 89 |
data suggests | 89 |
internal medicine | 89 |
monoclonal anti | 89 |
qiaamp viral | 89 |
pleural effusion | 89 |
rsv infection | 89 |
density gradient | 89 |
comparative analysis | 89 |
least days | 89 |
cleavage site | 89 |
respiratory illnesses | 89 |
among different | 89 |
dna detection | 89 |
bacterial growth | 89 |
laboratory test | 89 |
rna template | 89 |
usa introduction | 89 |
significant role | 89 |
extraction method | 89 |
often used | 88 |
external quality | 88 |
also increased | 88 |
human cases | 88 |
may develop | 88 |
study revealed | 88 |
study conducted | 88 |
merkel cell | 88 |
clinical suspicion | 88 |
like receptors | 88 |
showed similar | 88 |
matched related | 88 |
dis doi | 88 |
nosocomial infections | 88 |
ms plp | 88 |
diagnostic method | 88 |
bacterial culture | 88 |
binding domain | 88 |
genbank database | 88 |
gene mutation | 88 |
two types | 88 |
highly variable | 88 |
hsct recipients | 88 |
blood transfusions | 88 |
first trimester | 88 |
mean number | 88 |
size distribution | 88 |
total body | 88 |
icu patients | 88 |
hemorrhagic fever | 88 |
central role | 88 |
ha gene | 88 |
pulmonary hypertension | 87 |
found positive | 87 |
patient outcomes | 87 |
control dogs | 87 |
scid mice | 87 |
second round | 87 |
cell population | 87 |
library preparation | 87 |
performance characteristics | 87 |
medical record | 87 |
three samples | 87 |
using either | 87 |
molecular evolutionary | 87 |
partial remission | 87 |
influenza vaccination | 87 |
human adenoviruses | 87 |
chronic liver | 87 |
environmental conditions | 87 |
nasopharyngeal samples | 87 |
signal amplification | 87 |
associated coronavirus | 87 |
dna template | 87 |
primary care | 87 |
environmental factors | 87 |
lymphocyte count | 87 |
fatality rate | 87 |
expression profiling | 87 |
flight mass | 87 |
also shown | 87 |
community acquired | 87 |
female patients | 87 |
new cases | 87 |
primary human | 87 |
th cells | 87 |
using primer | 86 |
wistar rats | 86 |
clinical settings | 86 |
chikungunya virus | 86 |
clinical applications | 86 |
assay results | 86 |
genomic sequence | 86 |
en las | 86 |
detection assays | 86 |
fluorescence microscopy | 86 |
urinary bladder | 86 |
different clinical | 86 |
low molecular | 86 |
test kit | 86 |
male patients | 86 |
hla class | 86 |
fold change | 86 |
oral cavity | 86 |
autoimmune disease | 86 |
high expression | 86 |
endemic areas | 86 |
treatment option | 86 |
plant viruses | 86 |
health status | 86 |
interest reported | 86 |
nutritional status | 86 |
antibody screen | 86 |
transfusion practice | 86 |
adaptive immune | 86 |
virus using | 86 |
high concentrations | 86 |
transfusion therapy | 86 |
cell carcinomas | 86 |
specific probes | 86 |
long time | 86 |
serum concentrations | 86 |
urgent need | 85 |
negative pcr | 85 |
new therapeutic | 85 |
also present | 85 |
also demonstrated | 85 |
virus load | 85 |
high number | 85 |
induced apoptosis | 85 |
multiplex assay | 85 |
myelodysplastic syndrome | 85 |
image analysis | 85 |
high fat | 85 |
key words | 85 |
female donors | 85 |
fluorescent signal | 85 |
acute asthma | 85 |
significant impact | 85 |
extracellular vesicle | 85 |
also positive | 85 |
novel human | 85 |
true positive | 85 |
pcr positivity | 85 |
white spot | 85 |
per unit | 85 |
evidence suggests | 85 |
first week | 85 |
dna copies | 85 |
data showed | 84 |
respiratory panel | 84 |
died due | 84 |
human dna | 84 |
pathogen identification | 84 |
protein synthesis | 84 |
nanopore sequencing | 84 |
indirect immunofluorescence | 84 |
expression studies | 84 |
treatment groups | 84 |
related complications | 84 |
live attenuated | 84 |
molecular beacons | 84 |
molecular typing | 84 |
organ failure | 84 |
sample volume | 84 |
apoptotic cells | 84 |
england biolabs | 84 |
viral hepatitis | 84 |
flow rate | 84 |
mean values | 84 |
within months | 84 |
tract specimens | 84 |
agar dilution | 84 |
old girl | 84 |
resonance imaging | 84 |
cell depletion | 83 |
los casos | 83 |
plaque assay | 83 |
cd count | 83 |
last decade | 83 |
immune cell | 83 |
haploidentical donor | 83 |
con un | 83 |
significantly elevated | 83 |
realtime rt | 83 |
data support | 83 |
like virus | 83 |
pcr techniques | 83 |
recently reported | 83 |
several days | 83 |
virus shedding | 83 |
cause severe | 83 |
term follow | 83 |
mm patients | 83 |
previously identified | 83 |
mixed chimerism | 83 |
time interval | 83 |
recombinant protein | 83 |
disease onset | 83 |
positive bacteria | 83 |
rank test | 83 |
glass opacities | 83 |
specific amplification | 83 |
lamina propria | 83 |
nasal discharge | 83 |
human cytomegalovirus | 83 |
residual disease | 83 |
con una | 83 |
first round | 83 |
rna interference | 82 |
sexually transmitted | 82 |
potential therapeutic | 82 |
hcv genotype | 82 |
may reduce | 82 |
using high | 82 |
statistical difference | 82 |
neurological signs | 82 |
con sospecha | 82 |
medical research | 82 |
i ii | 82 |
wild birds | 82 |
national center | 82 |
hiv positive | 82 |
turkey objective | 82 |
different countries | 82 |
stage iii | 82 |
cells per | 82 |
based method | 82 |
pivotal role | 82 |
outer membrane | 82 |
also investigated | 82 |
chicken eggs | 82 |
virus detected | 82 |
immune deficiency | 82 |
positivity rate | 82 |
schwann cells | 82 |
muscle actin | 82 |
cell number | 82 |
positive sars | 82 |
agarose gels | 82 |
medical staff | 82 |
gram negative | 82 |
particle size | 82 |
designed using | 82 |
chronic graft | 82 |
reporter gene | 82 |
standard methods | 82 |
results demonstrated | 82 |
salivary gland | 82 |
taqman rt | 81 |
group system | 81 |
new method | 81 |
paciente con | 81 |
small rnas | 81 |
fat diet | 81 |
rna sequences | 81 |
high morbidity | 81 |
small sample | 81 |
method used | 81 |
within minutes | 81 |
successfully treated | 81 |
pcr buffer | 81 |
causative agents | 81 |
step real | 81 |
based tests | 81 |
relapse rate | 81 |
case definition | 81 |
one hour | 81 |
using molecular | 81 |
medical school | 81 |
showed higher | 81 |
body condition | 81 |
way anova | 81 |
human lung | 81 |
south america | 81 |
qpcr assays | 81 |
fecal specimens | 81 |
systemic lupus | 81 |
gene transcription | 81 |
oxygen saturation | 81 |
reference sequence | 81 |
infectious agent | 81 |
low concentrations | 81 |
mixed infection | 81 |
biological activity | 81 |
per week | 81 |
pneumoniae infection | 81 |
infected dogs | 81 |
bacterial pneumonia | 81 |
time donors | 80 |
adhesion molecules | 80 |
clinical application | 80 |
clinical response | 80 |
probe sequences | 80 |
mosaic virus | 80 |
therapeutic strategies | 80 |
examination showed | 80 |
distilled water | 80 |
tissue specimens | 80 |
mesenteric lymph | 80 |
water bath | 80 |
decision making | 80 |
rapid test | 80 |
microbiology laboratories | 80 |
hospital admissions | 80 |
using three | 80 |
magna pure | 80 |
membrane potential | 80 |
viral diarrhea | 80 |
influenza vaccines | 80 |
study demonstrated | 80 |
different viruses | 80 |
filtration rate | 80 |
promoter activity | 80 |
also associated | 80 |
neutralizing antibody | 80 |
male patient | 80 |
tumor size | 80 |
clinical study | 80 |
salmonella spp | 80 |
antibody production | 80 |
human airway | 80 |
cells ml | 80 |
patient groups | 80 |
household contacts | 80 |
showed significantly | 80 |
less likely | 80 |
venous blood | 80 |
control mice | 79 |
droplet digital | 79 |
enveloped viruses | 79 |
donate blood | 79 |
surface markers | 79 |
female patient | 79 |
ribosomal rna | 79 |
newly developed | 79 |
pasteurella multocida | 79 |
kans op | 79 |
arachidonic acid | 79 |
evolutionary genetics | 79 |
energy transfer | 79 |
five different | 79 |
mean duration | 79 |
se han | 79 |
host range | 79 |
hydrogen peroxide | 79 |
maximum likelihood | 79 |
significantly better | 79 |
adhesion molecule | 79 |
dose dependent | 79 |
organ transplantation | 79 |
acute lung | 79 |
final diagnosis | 79 |
sample types | 79 |
clostridium perfringens | 79 |
control patients | 79 |
platelet function | 79 |
technical assistance | 79 |
field samples | 79 |
pcr systems | 79 |
human pathogens | 79 |
total dna | 79 |
brain injury | 79 |
viral clearance | 79 |
solid tumors | 79 |
patient group | 79 |
testing using | 79 |
icu admission | 79 |
cell response | 78 |
routine diagnostic | 78 |
sialic acid | 78 |
main cause | 78 |
ferritin levels | 78 |
routinely used | 78 |
asymptomatic carriers | 78 |
infected pigs | 78 |
ibv strains | 78 |
efsa supporting | 78 |
previously demonstrated | 78 |
feline herpesvirus | 78 |
resistant isolates | 78 |
research complications | 78 |
comparative study | 78 |
transplanted patients | 78 |
type iii | 78 |
antibody levels | 78 |
tests performed | 78 |
russian federation | 78 |
vaccine development | 78 |
metapneumovirus infection | 78 |
patient age | 78 |
patient presented | 78 |
viral titers | 78 |
medium containing | 78 |
infected children | 78 |
index case | 78 |
gastric cancer | 78 |
interquartile range | 78 |
multiple pathogens | 78 |
fetal bovine | 78 |
significant proportion | 78 |
transfusion reaction | 78 |
supporting publication | 78 |
dna extracted | 78 |
diagnostic yield | 78 |
first described | 78 |
significant number | 78 |
genetic characterization | 77 |
weeks later | 77 |
using dna | 77 |
complementary dna | 77 |
cost effective | 77 |
porcine apn | 77 |
important roles | 77 |
diagnostic assay | 77 |
isolation kit | 77 |
preterm birth | 77 |
strand rna | 77 |
bartonella spp | 77 |
probe set | 77 |
genomic sequences | 77 |
clinical parameters | 77 |
readily available | 77 |
detect viral | 77 |
asthma control | 77 |
months old | 77 |
blood banking | 77 |
molecular basis | 77 |
patients included | 77 |
emergency use | 77 |
tumor suppressor | 77 |
kg bw | 77 |
renal insufficiency | 77 |
odds ratios | 77 |
values obtained | 77 |
animal species | 77 |
also determined | 77 |
solid phase | 77 |
three weeks | 77 |
connective tissue | 77 |
donor screening | 77 |
respiratory system | 77 |
new insights | 77 |
model system | 77 |
therapeutic option | 77 |
speci fi | 77 |
showed positive | 77 |
forming units | 77 |
lipid peroxidation | 77 |
exogenous rnas | 77 |
state university | 77 |
legionella pneumophila | 77 |
associated pneumonia | 77 |
line therapy | 77 |
patients tested | 77 |
two main | 77 |
size exclusion | 77 |
voluntary blood | 77 |
viruses including | 77 |
stimulating factor | 76 |
normal human | 76 |
large amounts | 76 |
antibody titer | 76 |
prospective cohort | 76 |
assess whether | 76 |
higher rates | 76 |
testing methods | 76 |
genetic testing | 76 |
human blood | 76 |
acute rejection | 76 |
fold dilution | 76 |
sample processing | 76 |
animal medicine | 76 |
derived exosomes | 76 |
different tissues | 76 |
specific binding | 76 |
agar plates | 76 |
conditioned media | 76 |
massive transfusion | 76 |
patient underwent | 76 |
successfully used | 76 |
fetal growth | 76 |
may require | 76 |
inflammatory markers | 76 |
induced sputum | 76 |
average number | 76 |
pneumoniae isolates | 76 |
etiologic agent | 76 |
less frequently | 76 |
oligonucleotide probes | 76 |
cases showed | 76 |
posted august | 76 |
spot syndrome | 76 |
will require | 75 |
cellular uptake | 75 |
ionization mass | 75 |
care units | 75 |
genetics analysis | 75 |
disease course | 75 |
related viruses | 75 |
five days | 75 |
cell survival | 75 |
correctly identified | 75 |
pulmonary embolism | 75 |
fetal dna | 75 |
days prior | 75 |